[Parameters of bone tissue density in patients with bronchial asthma].
OBJECTIVE
To study bone density in patients with bronchial asthma (BA).


METHODS
Bone densitometric indices were evaluated in 123 patients with BA in relation to the basic therapy, dosage, and the duration and severity of the disease.


RESULTS
The bulk (59.3%) of BA patients is found to have the osteopenic syndrome whose detection rate increases with longer duration and greater severity. Decreased bone density is more evident with oral glucocorticoids (GCs) than with inhaled ones. The effect of topical GCs on bone density is determined by their bioavailability. The decrease in bone density is more noticeable in patients taking beclomethasone and minimal in those on basic fluticasone therapy.


CONCLUSIONS
Considerable decreases in bone density in BA patients may be prevented by a rational basic therapy with first-line inhaled GCs with low bioavailability.
Gel'tser
B I
BI
Kochetkova
E A
EA
D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D015519:Bone Density; D004333:Drug Administration Routes; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D014463:Ultrasonography
D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids